reports
- Sean Conroy
Vivesto - Termination of coverage
Edison Investment Research is terminating coverage on Vivesto (VIVE), Diurnal Group (DNL), Palace Capital (PCA), Primary Health Properties (PHP), Silver One Resources (SVE), Induction Healthcare (INHC) and Axiom European Financial Debt (AXI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
- Sean Conroy
Vivesto - Turnaround strategy beginning to deliver
Vivesto capped off its 18-month strategic turnaround with reduced Q1 losses and a stated focus on its ‘string of pearls’ strategy to build its oncology pipeline through in-licensing and M&A. In March, it successfully completed a rights issue, generating net proceeds of SEK134.6m, extending its runway into 2024. This is sufficient to cover a number of clinical and commercial inflection points and execute its strategy. Key upcoming catalysts include the planned 2022 UK and German launches of Apeal...
- Sean Conroy
Oasmia Pharmaceutical - Delivering on promises
FY21 results highlight delivery on key elements of Oasmia’s ongoing transformation. Notably, ‘rightsizing’ the business and prudent cost control has brought the underlying cash burn rate down to c SEK10m per month in 2021. With the fully secured rights issue expected to raise gross proceeds of c SEK150m, management has guided it can fund operations for 18–24 months. We anticipate material progression can be made across the pipeline during this time, with clinical progress expected from Cantrixil...
- Sean Conroy
Oasmia Pharmaceutical - Rights issues secured and planned for Q122
Oasmia has announced it has secured a preferential, one-for-five rights issue that will raise gross proceeds of c SEK151m and should alleviate near-term funding requirements. The company’s largest shareholder has agreed to subscribe to its allotment (24.8%) and a consortium of external investors has guaranteed the remainder (75.2%), albeit on a 6.5% cash compensation basis. Subscription rights can be traded from 8 to 17 March. Oasmia has also announced plans to change its name to Vivesto; both t...
- Sean Conroy
Oasmia Pharmaceutical - Rights issues secured and planned for Q122
Oasmia has announced it has secured a preferential, one-for-five rights issue that will raise gross proceeds of c SEK151m and should alleviate near-term funding requirements. The company’s largest shareholder has agreed to subscribe to its allotment (24.8%) and a consortium of external investors has guaranteed the remainder (75.2%), albeit on a 6.5% cash compensation basis. Subscription rights can be traded from 8 to 17 March. Oasmia has also announced plans to change its name to Vivesto; both t...
- Sean Conroy
Oasmia Pharmaceutical - A definitive year ahead
We believe Oasmia is entering a definitive phase of its transformation in the months ahead. Apealea is due to be launched in Europe (early 2022), enabling an inflow of commercial revenues in 2022. Importantly however, licensee Elevar has notified Oasmia that it is reviewing the previously communicated strategy for Apealea in the United States; we note that accelerating timelines (expected launch 2025) or expansion into indications beyond advanced ovarian cancer could potentially present upside t...
- Sean Conroy
Oasmia Pharmaceutical - A definitive year ahead
We believe Oasmia is entering a definitive phase of its transformation in the months ahead. Apealea is due to be launched in Europe (early 2022), enabling an inflow of commercial revenues in 2022. Importantly however, licensee Elevar has notified Oasmia that it is reviewing the previously communicated strategy for Apealea in the United States; we note that accelerating timelines (expected launch 2025) or expansion into indications beyond advanced ovarian cancer could potentially present upside t...
Oasmia Pharmaceutical (OASM): Focused on pillars of growth
Edison Investment Research Limited Oasmia Pharmaceutical (OASM): Focused on pillars of growth 08-Oct-2021 / 10:18 GMT/BST London, UK, 8 October 2021 Oasmia Pharmaceutical (OASM): Focused on pillars of growth Oasmia Pharmaceutical has made steady progress in its ongoing transition into an R&D-driven, speciality pharma company with commercially available assets. The in-licensing of Cantrixil from Kazia Therapeutics in March is the first of its 'string of pearls' strategy to bolster the pipeline. Oasmia now has three oncology assets under its belt. Partner Elevar Therapeutics n...
- Sean Conroy
Oasmia Pharmaceutical - Focused on pillars of growth
Oasmia Pharmaceutical has made steady progress in its ongoing transition into an R&D-driven, speciality pharma company with commercially available assets. The in-licensing of Cantrixil from Kazia Therapeutics in March is the first of its ‘string of pearls’ strategy to bolster the pipeline. Oasmia now has three oncology assets under its belt. Partner Elevar Therapeutics now expects to initiate the additional trials required by the FDA to enable the NDA submission for Apealea (Cremophor-free pacli...
- Sean Conroy
Oasmia Pharmaceutical - Focused on pillars of growth
Oasmia Pharmaceutical has made steady progress in its ongoing transition into an R&D-driven, speciality pharma company with commercially available assets. The in-licensing of Cantrixil from Kazia Therapeutics in March is the first of its ‘string of pearls’ strategy to bolster the pipeline. Oasmia now has three oncology assets under its belt. Partner Elevar Therapeutics now expects to initiate the additional trials required by the FDA to enable the NDA submission for Apealea (Cremophor-free pacli...
Oasmia Pharmaceutical AB: 2 directors
Two Directors at Oasmia Pharmaceutical AB bought 61,000 shares at between 2.910SEK and 2.960SEK. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
- Sean Conroy
Oasmia Pharmaceutical - Onwards and upwards
Oasmia is at a major inflection point as it focuses on its transformation into an R&D-driven, specialty pharma company, with commercially available assets. During 2020, with new management at the helm, much progress was made, including the global partnership deal with Elevar Therapeutics for lead oncology asset Apealea (Cremophor-free paclitaxel), and the implementation of significant cost saving programs. Management has kickstarted 2021 with the in-licensing of Cantrixil (in all indications) fr...
- Sean Conroy
Oasmia Pharmaceutical - Clarity on pathway to US approval
Oasmia’s H1 FY21 results highlight recent developments made to realign the business. In December, global partner Elevar Therapeutics announced it had concluded discussions with the FDA on the pathway to US approval for Apealea (Cremophor-free paclitaxel) in ovarian cancer. The FDA has stated it requires two additional trials to form the basis of the NDA submission. We have delayed our forecast US launch by two years to 2025, which means our forecast timeframe to maiden profitability has now shif...
Edison Investment Research Limited: Edison issues initiation on Oasmia...
Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Oasmia Pharmaceutical (OASM) 09-Sep-2020 / 14:59 GMT/BST Â London, UK, 9 September 2020 Edison issues initiation on Oasmia Pharmaceutical (OASM) Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs through its proprietary XR-17 platform technology. Its technology has received validation though a global partnership deal for lead asset Apealea (Cremophor-free paclitaxel) with Elevar Therapeutics across a variety of cancer i...
Oasmia håller presentation på Biotech Showcase i San Francisco
Oasmia håller presentation på Biotech Showcase i San Francisco Oasmia Pharmaceutical AB har blivit utvalda att hålla en presentation på branschkonferensen Biotech Showcase i San Francisco. Bolaget kommer att presentera sin teknologi tisdagen den 14 januari kl 15:30, Track Yosemite C (Ballroom level). Biotech Showcase Conference, som pågår 13–15 januari 2020, är en av branschens ledande bransch- och investerarkonferenser med drygt 3 700 deltagare, 2 200 företag och 1 000 investerare. Konferensen, som arrangeras av Demy-Colton och EBD Group, är en investerar- och nätverkskonferens som erb...
Oasmia to present at Biotech Showcase in San Francisco
Oasmia to present at Biotech Showcase in San Francisco Oasmia Pharmaceutical AB has been selected to present at the Biotech Showcase Conference and will be presenting its technology on Tuesday 14 January at 15:30 (3:30 pm), Track Yosemite C (Ballroom level). Biotech Showcase Conference, January 13–15, 2020, is one of the industry’s leading industry and investor conferences expecting more than 3,700 attendees, 2,200 companies, and over 1,000 investors. The conference, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biot...
New number of shares and votes in Oasmia Pharmaceutical AB (publ)
New number of shares and votes in Oasmia Pharmaceutical AB (publ) The number of shares and votes in Oasmia Pharmaceutical AB (publ) has increased as a result of the preferential rights issue completed in December 2019. As a result of the preferential rights issue, the number of shares and votes has increased by 199,275,352 from 249,094,194 to 448,369,546. The share capital has increased by SEK 19,927,535.20 from SEK 24,909,419.40 to SEK 44,836,954.60. For more information:Urban Ekelund, Investor Relations OasmiaE-mail: Phone: This information is information that Oasmia Pharmaceutical ...
Nytt antal aktier och röster i Oasmia Pharmaceutical AB (publ)
Nytt antal aktier och röster i Oasmia Pharmaceutical AB (publ) Antalet aktier och röster i Oasmia Pharmaceutical AB (publ) har ökat med anledning av den företrädesemission som slutfördes i december 2019. Som ett resultat av företrädesemisisonen har antalet aktier och röster ökat med 199 275 352 från 249 094 194 till 448 369 546. Aktiekapitalet har ökat med 19 927 535,20 kronor från 24 909 419,40 kronor till 44 836 954,60 kronor. För mer information:Urban Ekelund, IR-chef Oasmia E-post: Telefon: 018-50 54 40 Denna information är sådan information som Oasmia Pharmaceutical AB (publ) är sk...
Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 â€...
Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – October 31, 2019 EVENTS IN SECOND QUARTER Oasmia ADSs were delisted from NASDAQ in the US to reduce complexity and costs.Oasmia recruited two General Managers to its management team.Oasmia published its annual report for 2018/2019 and adjusted accounts due to write-downs. The company’s auditors did not recommend former Board to be granted discharge from liability.The special examiner appointed by Oasmia’s Board, Svante Forsberg (Deloitte), submitted his report on investigation of liability issues ahead of the upcoming ...
Oasmia Pharmaceutical AB (publ) Delårsrapport för perioden 1 maj –...
Oasmia Pharmaceutical AB (publ) Delårsrapport för perioden 1 maj – 31 oktober 2019 HÄNDELSER UNDER ANDRA KVARTALET Oasmias depåbevis avnoterades från NASDAQ i USA för att minska komplexitet och kostnader.Oasmia rekryterade två General Managers till bolagets ledningsgrupp. Oasmia publicerade sin årsredovisning för 2018/2019 och reviderade räkenskaper efter nedskrivningar. Bolagets revisor avstyrkte beviljande av ansvarsfrihet för tidigare styrelse.Den av Oasmias styrelse anlitade särskilde granskaren, Svante Forsberg (Deloitte), lämnade sin rapport kring utredning av ansvarsfrågor inför...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.